If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenedrive Regulatory News (GDR)

Share Price Information for Genedrive (GDR)

Share Price is delayed by 15 minutes
Get Live Data
1.30    0.00 (0.00%)
Bid:
1.25
Ask:
1.35
Spread: 0.10 (8.00%)
Market Cap: £20.87m
GDR Live PriceLast checked at - London Stock Exchange

Intraday Genedrive Share Chart

Distribution agreement

9 Mar 2021 07:00

RNS Number : 5536R
Genedrive PLC
09 March 2021
 

 

 

genedrive plc

("genedrive" or the "Company")

 

Genedrive enters distribution agreement with Mountain Horse Solutions

Distribution of genedrive's Military Assays and Instrument in the United States

 

genedrive plc (AIM: GDR), the near patient molecular diagnostics company, announces that it has entered into an agreement for the distribution of the Company's military pathogen detection assays in the United States with Mountain Horse Solutions ("Mountain Horse"), a military contracting specialist to U.S. Federal, State, and Local Government customers.

 

genedrive has a unique product with regard to military CBRNE1 requirements. The Genedrive® BioPlex range of products was developed to the U.S. Department of Defense's (U.S. DoD) product specification with the help of U.S. DoD funding. Designed for field portability and rapid determination of biothreats from pathogens, the Genedrive BioPlex system was developed over a period of five years and has been approved to deployment stage.

 

Contracting with the U.S. Government can be challenging and time consuming. The Company believes that establishing new, local representation in the United States with identified contacts in this highly specialised field will help drive broader product uptake. Organisations like Mountain Horse are already contracted with the U.S. Government, which includes existing framework purchasing agreements, providing an opportunity for more rapid order placement and replenishment of products without the need for new contracts to be negotiated.

 

Bill Allen, President of Mountain Horse Solutions, said: "We are delighted to be working with genedrive with these exciting pathogen detection products. The addition of genedrive's assays to our portfolio of CBRNE mission critical products provides a unique offering of combat-ready sampling and detection devices."

 

David Budd, CEO of genedrive plc, said: "The agreement allows the supply of our BioPlex pathogen detection assays through Mountain Horse, a military contracting specialist who has a number of existing framework contracts with target clients such as the U.S. DoD. We believe that they have both the industry sector knowledge and existing commercial arrangements to increase the exposure of our products and gain new customer opportunities within the various branches and departments of the DoD and U.S. Government."

 

1. Chemical Biological Radiological, Nuclear and Explosive

 

For further details please contact:

 

genedrive plc

+44 (0)161 989 0245

David Budd: CEO / Matthew Fowler: CFO

 

 

 

Peel Hunt LLP (Nominated Adviser and Joint Broker)

+44 (0)20 7418 8900

James Steel / Oliver Jackson

 

 

 

finnCap (Joint Broker)

+44 (0)20 7220 0500

Geoff Nash / Kate Bannatyne / Alice Lane

 

 

 

Walbrook PR Ltd (Media & Investor Relations)

+44 (0)20 7933 8780 or genedrive@walbrookpr.com

Paul McManus / Anna Dunphy

+44 (0)7980 541 893 / +44 (0)7876 741 001

 

 

About genedrive plc (http://www.genedriveplc.com) genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Company has assays on market for the detection of HCV, certain military biological targets, and has tests in development for tuberculosis (mTB). The Company recently released a high throughput SARS-CoV-2 assay and has in development a Genedrive® Point of Care version of the assay, both based on Genedrive® chemistry.

 

About Mountain Horse Solutions 

Mountain Horse Solutions supplies rapid response customized equipment, systems, and training for infectious disease, security, technology, chemical, biological, radiological, nuclear, and explosive (CBRNE) hazards. We specially design innovative solutions, to meet the individual unique threats, needs, and requirements of the military, and first responders. Our team of professionals from around the globe has extensive experience with commercial, DOD, and U.S. Federal Government customers. Mountain Horse Solutions serves organizations, agencies, and contractors worldwide. To find out more visit: www.mtnhorse.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
AGRBIGDXBXGDGBI
Date   Source Headline
10th Sep 20215:03 pmRNSResult of Placing
10th Sep 20214:40 pmRNSSecond Price Monitoring Extn
10th Sep 20214:35 pmRNSPrice Monitoring Extension
10th Sep 20212:01 pmRNSProposed Placing and Open Offer
31st Aug 20217:00 amRNSNew Genedrive system readied for AIHL launch
1st Jul 20217:00 amRNSGenedrive COVID-19 Point of Care device update
25th Jun 20214:40 pmRNSSecond Price Monitoring Extn
25th Jun 20214:35 pmRNSPrice Monitoring Extension
25th Jun 20211:17 pmRNSGenedrive confirms receipt of India Import License
25th Jun 202111:05 amRNSSecond Price Monitoring Extn
25th Jun 202111:00 amRNSPrice Monitoring Extension
22nd Jun 202111:05 amRNSSecond Price Monitoring Extn
22nd Jun 202111:00 amRNSPrice Monitoring Extension
28th May 20216:00 pmRNSBlock listing Interim Review
28th May 20214:40 pmRNSSecond Price Monitoring Extn
28th May 20214:35 pmRNSPrice Monitoring Extension
6th May 20212:05 pmRNSSecond Price Monitoring Extn
6th May 20212:00 pmRNSPrice Monitoring Extension
30th Apr 20217:00 amRNSCOVID-19 PCR test approved by Indian regulator
23rd Apr 20217:00 amRNSExcellent performance data for Genedrive® HCV test
19th Apr 20217:00 amRNSPHE National Framework Agreement
1st Apr 20217:00 amRNSTotal Voting Rights
31st Mar 202111:05 amRNSSecond Price Monitoring Extn
31st Mar 202111:00 amRNSPrice Monitoring Extension
25th Mar 20217:00 amRNSHalf-year Report
9th Mar 20217:00 amRNSDistribution agreement
3rd Mar 20217:00 amRNSAntibiotic Induced Hearing Loss update
1st Mar 20214:41 pmRNSSecond Price Monitoring Extn
1st Mar 20214:35 pmRNSPrice Monitoring Extension
1st Mar 20217:00 amRNSInvestor Presentation
1st Mar 20217:00 amRNSTotal Voting Rights
17th Feb 20217:00 amRNSFirst US shipments of Genedrive® 96 SARS-CoV-2 Kit
12th Feb 20212:10 pmRNSHolding(s) in Company
10th Feb 20219:05 amRNSSecond Price Monitoring Extn
10th Feb 20219:00 amRNSPrice Monitoring Extension
9th Feb 20212:28 pmRNSHolding(s) in Company
8th Feb 20213:30 pmRNSHolding(s) in Company
8th Feb 202112:51 pmRNSHolding(s) in Company
8th Feb 202111:05 amRNSSecond Price Monitoring Extn
8th Feb 202111:00 amRNSPrice Monitoring Extension
2nd Feb 20212:05 pmRNSHolding(s) in Company
2nd Feb 20219:05 amRNSSecond Price Monitoring Extn
2nd Feb 20219:00 amRNSPrice Monitoring Extension
1st Feb 20211:22 pmRNSHolding(s) in Company
1st Feb 20219:05 amRNSSecond Price Monitoring Extn
1st Feb 20219:00 amRNSPrice Monitoring Extension
1st Feb 20217:00 amRNSTotal Voting Rights
29th Jan 20219:05 amRNSSecond Price Monitoring Extn
29th Jan 20219:00 amRNSPrice Monitoring Extension
28th Jan 20219:05 amRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.